Aldena Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Biotechnology development of siRNA-based treatments for skin conditions.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Financing and pipeline update
On March 16, 2023, Aldena Therapeutics announces a $30 million financing by Medicxi, a pipeline of six siRNA compounds for immuno-dermatology (three slated for IND filing the next year), and a Scientific Advisory Board chaired by Nobel laureate Craig Mello; the company was co-founded by John Harris, Mark Prausnitz, and Andrew Tadros and is led by CEO Thibaud Portal.
- Manufacturing partnership
In October 2023, Aldena selects PCI Pharma Services to formulate, package, and distribute ALD-102, its siRNA-based injectable treatment for inflammatory dermatological conditions, then in preclinical trials as the most advanced therapy in its pipeline.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.